–  Utilizing Ascletis’ Peptide Oral Transport ENhancement Technology (POTENT), ASC37 oral tablets achieved average absolute oral bioavailability of 4.2%, approximately 9–, 30–, and 60-fold higher than semaglutide, tirzepatide, and retatrutide in the oral SNAC formulation, respectively, in head-to-head non-human primate (NHP) studies.

–  ASC37 oral tablets’ drug exposure, as measured by the area under curve (AUC), was approximately 57-fold of retatrutide’s drug exposure in head-to-head NHP studies.

–  Average observed half-life of ASC37 oral tablets was approximately 56 hours in NHP studies, supporting once daily and less frequent oral dosing.

–  ASC37 in vitro activity was approximately 5-, 4- and 4-fold more potent than retatrutide for GLP-1R, GIPR and GCGR, respectively.

–  Submission of an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for ASC37 oral tablets is expected in the second quarter of 2026.

–  The Company will host a conference call in Mandarin at 10:00 a.m. China Standard Time on December 1, 2025.

HONG KONG, Nov. 30, 2025 /PRNewswire/ — Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) announces that it has selected ASC37 oral tablets, its first oral GLP-1R/GIPR/GCGR^[1] triple peptide agonist, as a clinical development candidate. Ascletis expects to submit an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for ASC37 oral tablets for the treatment of obesity in the second quarter of 2026.

ASC37 oral tablets is the Company’s first incretin drug candidate developed with its proprietary Peptide Oral Transport ENhancement Technology (POTENT). 

ASC37, a GLP-1R, GIPR, and GCGR triple peptide agonist, was discovered and optimized in-house utilizing Ascletis’ Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD). ASC37 in vitro activity was approximately 5-, 4-, and 4-fold more potent than retatrutide for GLP-1R, GIPR and GCGR, respectively.

Utilizing Ascletis’ POTENT technology, ASC37 oral tablets achieved average absolute oral bioavailability^[2] of 4.2%, which was approximately 9-, 30-, and 60-fold higher than semaglutide, tirzepatide, and retatrutide in the oral SNAC ^[3] formulation, respectively, in head-to-head non-human primate (NHP) studies. Furthermore, after oral administration, ASC37 oral tablets’ drug exposure, as measured by the area under curve (AUC), with the POTENT formulation was approximately 57-fold of retatrutide’s drug exposure with the oral SNAC formulation, in head-to-head NHP studies.

Average observed half-life of ASC37 oral tablets was approximately 56 hours in NHP studies, supporting once daily and less frequent oral dosing.

 “Selection of ASC37, a promising oral GLP-1R/GIPR/GCGR triple peptide agonist, for clinical development once again demonstrates our strong R&D capabilities and our commitment to address the unmet needs for the treatment of obesity,” said Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis, “Leveraging our proprietary technology platforms, including AISBDD and POTENT, Ascletis has successfully established a highly competitive, differentiated and diverse pipeline portfolio which can potentially effectively address the various treatment needs of patients with obesity and other metabolic diseases.”

Conference Call

Ascletis will host a conference call in Mandarin at 10:00 a.m. China Standard Time on December 1, 2025. A live webcast of the call will be available via Tencent Meeting/ VooV Meeting, with the Meeting ID: 495-266-842, or access links of:

Chinese Mainland: https://meeting.tencent.com/dm/10ve6whW8Rbl; or

International: https://voovmeeting.com/dm/10ve6whW8Rbl.

About Ascletis Pharma Inc.

Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases. Utilizing its proprietary Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies as well as Peptide Oral Transport ENhancement Technology (POTENT), Ascletis has developed multiple drug candidates in-house, including both small molecules and peptides, such as its lead program, ASC30, a small molecule GLP-1R agonist designed to be administered once daily orally and once monthly to once quarterly subcutaneously as a treatment therapy and a maintenance therapy for chronic weight management; ASC36, a once-monthly subcutaneously administered amylin receptor peptide agonist, ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist and ASC37, an oral GLP-1R/GIPR/GCGR triple peptide agonist for chronic weight management. Ascletis is listed on the Hong Kong Stock Exchange (1672.HK).

For more information, please visit www.ascletis.com.

Contact：

Peter Vozzo
ICR Healthcare
443-231-0505 (U.S.)
Peter.vozzo@icrhealthcare.com 

Ascletis Pharma Inc. PR and IR teams
+86-181-0650-9129 (China)
pr@ascletis.com
ir@ascletis.com 

BEIJING, Nov. 30, 2025 /PRNewswire/ — Do you want to visit China? How to travel as convenient as a local resident? You can learn from this guide! There are three foreign residents from different countries to show you the mobile payments, transportation and local cuisine. Come and get the shortcut!

Original link: https://en.imsilkroad.com/p/348542.html

SHANGHAI, Nov. 30, 2025 /PRNewswire/ — On the afternoon of November 26, a major Grade 5 fire spread across multiple residential buildings in Wang Fuk Court in Tai Po, Hong Kong, causing severe casualties and drawing widespread public concern. In response, on November 28, Qiming Venture Partners made a donation of HK$3 million to the Tai Po Wang Fuk Court Aid Fund established by the Hong Kong SAR Government, to support affected residents and contribute to post-disaster reconstruction.

The Hong Kong SAR Government established the Tai Po Wang Fuk Court Aid Fund on November 27, with an initial allocation of HK$300 million, to coordinate social resources and fully carry out rescue and recovery support. The fund is also open to donations from the public, aiming to unite support from all walks of life to facilitate efficient aid distribution. Qiming Venture Partners responded promptly with this donation, to assist those affected while fulfilling its corporate social responsibility.

Qiming Venture Partners expresses our condolences to the families impacted by the major fire, and our deepest respect to the firefighters and rescue personnel at the frontline. We are grateful for their exceptional professionalism and selfless dedication which were evident throughout the crisis. Qiming hopes that its contribution will help alleviate the challenges faced by affected residents and support their swift return to normal life. Qiming also calls on more social forces to join in the relief efforts and contribute to the rebuilding of the affected communities.

About Qiming Venture Partners

Qiming Venture Partners was founded in 2006. Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companies in the Technology and Healthcare industries at the early and growth stages.

Since our debut, we have backed over 580 fast-growing and innovative companies. Over 210 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 80 portfolio companies that have achieved unicorn or super unicorn status.

Many of our portfolio companies are today’s most influential firms in their respective sectors, including Xiaomi, Meituan, Bilibili, Zhihu, Roborock, HESAI, UBTech, WeRide, HyperStrong, Insta360, Unisound, Gan & Lee Pharmaceuticals, Tigermed, Zai Lab, CanSino Biologics, Schrödinger, APT Medical, Sanyou Medical, AmoyDx, SinocellTech, AusperBio, Yuanxin Technology, Insilico Medicine, Medilink Therapeutics, LaNova Medicines, zai, StepFun, among many others.

HO CHI MINH CITY, Vietnam, Nov. 29, 2025 /PRNewswire/ — A seminar on renewable energy and energy storage applications was held on November 28 in Ho Chi Minh City, Vietnam. The event fostered substantive discussions on next-generation solar systems, the strategic value of battery energy storage systems (BESS) in the energy transition, evolving two-part tariff structures, and targeted, forward-looking investment solutions. More than 100 attendees from industry associations, leading companies, and ecosystem partners joined the session to shape the future of clean energy in Vietnam. 

Seizing Opportunities, Ushering in a New Era for Residential Solar

In a keynote address, Ms. Shen Lu, national general distributor for Shenzhen Skyworth Photovoltaic Technology Co., Ltd. (“Skyworth PV”) in Vietnam, delivered a comprehensive analysis of the current landscape and future trajectory of Vietnam’s residential solar market. She emphasized Vietnam’s exceptional solar energy resources, noting an average annual sunlight exceeding 2,000 hours, which provides a natural foundation for solar power generation. At present, however, PV applications are mostly seen in large ground-mounted power stations and commercial or industrial rooftop systems, with relatively limited adoption among ordinary households.

Simplifying Complexity, Redefining Home Solar

To address these market gaps, Skyworth PV announced the official launch of its SUN Mate Home Solar 2.0 solution, the result of extensive market research and technological innovation. The core proposition of this new offering is “making clean energy accessible,” effectively transforming complex solar power generation into a product as straightforward and user-friendly as a standard household appliance. 

A defining feature of the SUN Mate series is its “plug-and-play” design. Unlike conventional solar installations that require professional design, complex construction, and structural modifications, SUN Mate truly achieves a “three no” principle: no design, no construction, and no modification needed. Homeowners are freed from concerns about complex installation requirements; whether for urban apartment balconies or rural home courtyards, a suitable and simple installation solution is readily available.

In everyday use, SUN Mate delivers equally impressive performance. The system produces power during daylight hours for direct household consumption, significantly cutting grid electricity usage and cost. Through Skyworth’s proprietary smart cloud platform and mobile app, users can monitor real-time generation data and equipment status, and connect with professional customer service when needed. This intelligent management experience—making solar energy “visible, manageable, and affordable”—enables households to adopt solar power effortlessly. 

Versatile Designs for Vietnamese Homes

To enable broader clean energy adoption across Vietnamese households, Skyworth PV has engineered three distinct SUN Mate product configurations, each meticulously optimized for specific settings.

The Balcony Model fits modern urban living. Its compact structure and minimalist design enable seamless integration with various architectural styles. The unique bracket-based setup requires no special tools and preserves building structures, making installation possible even for apartment dwellers. Designed to withstand Vietnam’s rainy and windy seasons, the model offers enhanced stability to maintain safety and reliability in adverse weather conditions.

The Awning Model strategically combines power generation with practical shade provision, making it particularly suitable for storefronts or the exteriors of owner-built houses. It not only supplies electricity and cuts energy costs, but also creates comfortable shaded spaces, delivering multiple functional benefits. Its stylish design also enhances a building’s visual appeal.

The Ground Model has drawn widespread attention for its superior adaptability. It supports angle adjustments between 25 and 40 degrees, allowing users to easily position it for optimal power generation based on seasonal variations and sun angles. Suitable for family yards, terraces, or campsites, the unit can also be folded and relocated with ease—bringing portable clean energy wherever needed. 

As awareness of clean energy grows and technology continues advancing, residential solar power is transitioning from a premium alternative to an essential household solution. Through its innovative products and user-centered design, Skyworth PV is opening the door to the clean energy era for Vietnamese households. On this path toward sustainability, Skyworth PV remains committed to partnering with families across Vietnam to collectively build a cleaner, more promising future.